Found: 14
Select item for more details and to access through your institution.
Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients.
- Published in:
- Molecular Therapy, 2015, v. 23, n. 3, p. 602, doi. 10.1038/mt.2014.243
- By:
- Publication type:
- Article
VEGF Blockade Enables Oncolytic Cancer Virotherapy in Part by Modulating Intratumoral Myeloid Cells.
- Published in:
- Molecular Therapy, 2013, v. 21, n. 5, p. 1014, doi. 10.1038/mt.2013.39
- By:
- Publication type:
- Article
Corrigendum: Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors.
- Published in:
- Frontiers in Immunology, 2024, p. 01, doi. 10.3389/fimmu.2024.1456897
- By:
- Publication type:
- Article
Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors.
- Published in:
- Frontiers in Immunology, 2024, p. 01, doi. 10.3389/fimmu.2024.1384623
- By:
- Publication type:
- Article
Engineered oncolytic virus for the treatment of cholesteatoma: A pilot in vivo study.
- Published in:
- Laryngoscope Investigative Otolaryngology, 2019, v. 4, n. 5, p. 532, doi. 10.1002/lio2.307
- By:
- Publication type:
- Article
Efficacy and Safety of the Oncolytic Herpes Simplex Virus rRp450 Alone and Combined With Cyclophosphamide.
- Published in:
- Molecular Therapy, 2008, v. 16, n. 5, p. 879, doi. 10.1038/mt.2008.49
- By:
- Publication type:
- Article
Oncolytic HSV and Erlotinib Inhibit Tumor Growth and Angiogenesis in a Novel Malignant Peripheral Nerve Sheath Tumor Xenograft Model.
- Published in:
- Molecular Therapy, 2007, v. 15, n. 2, p. 279, doi. 10.1038/sj.mt.6300038
- By:
- Publication type:
- Article
657. Combination Therapy with Cyclophosphamide and the Oncolytic Herpes Virus Mutant rRp450, Expressing a Cyclophosphamide Prodrug, Is Clinically Safe by Intratumoral, Intravenous, and Intracerebral Administration in an HSV-1 Susceptible Mouse Model.
- Published in:
- Molecular Therapy, 2006, v. 13, p. S253, doi. 10.1016/j.ymthe.2006.08.733
- By:
- Publication type:
- Article
658. Oncolytic Herpes Virus Mutants Are Efficacious Against Malignant Peripheral Nerve Sheath Tumor Xenografts.
- Published in:
- Molecular Therapy, 2006, v. 13, p. S253, doi. 10.1016/j.ymthe.2006.08.734
- By:
- Publication type:
- Article
Preparation and Evaluation of a Novel Class of Amphiphilic Amines as Antitumor Agents and Nanocarriers for Bioactive Molecules.
- Published in:
- Pharmaceutical Research, 2016, v. 33, n. 11, p. 2722, doi. 10.1007/s11095-016-1999-9
- By:
- Publication type:
- Article
Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses.
- Published in:
- Cancer Gene Therapy, 2005, v. 12, n. 4, p. 407, doi. 10.1038/sj.cgt.7700799
- By:
- Publication type:
- Article
Cancer Screening by Systemic Administration of a Gene Delivery Vector Encoding Tumor-Selective Secretable Biomarker Expression.
- Published in:
- PLoS ONE, 2011, v. 6, n. 5, p. 1, doi. 10.1371/journal.pone.0019530
- By:
- Publication type:
- Article
Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma.
- Published in:
- Pediatric Blood & Cancer, 2014, v. 61, n. 11, p. 2096, doi. 10.1002/pbc.25062
- By:
- Publication type:
- Article
Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models.
- Published in:
- Pediatric Blood & Cancer, 2005, v. 44, n. 5, p. 469, doi. 10.1002/pbc.20268
- By:
- Publication type:
- Article